Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Sep 20;39(27):3089-3090.
doi: 10.1200/JCO.21.01174. Epub 2021 Jul 6.

Who Can Receive the Benefit of a Palbociclib Add-On in Patients With HR+HER2- Breast Cancer With Residual Disease After Neoadjuvant Chemotherapy?

Yukino Kawamura  1 , Akihiko Shimomura  1 , Chikako Shimizu  1
Affiliations
Comment

Who Can Receive the Benefit of a Palbociclib Add-On in Patients With HR+HER2- Breast Cancer With Residual Disease After Neoadjuvant Chemotherapy?

Yukino Kawamura et al. J Clin Oncol. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Akihiko ShimomuraHonoraria: Chugai Pharma, AstraZeneca, Pfizer, Novartis, Eisai, Eli-Lilly, Daiichi Sankyo/UCB Japan, Kyowa Kirin InternationalConsulting or Advisory Role: Lilly Japan, AstraZeneca, PfizerResearch Funding: Chugai Pharma, AstraZeneca, Daiichi Sankyo, Mochida Pharmaceutical Co Ltd, Taiho Pharmaceutical Chikako ShimizuHonoraria: AstraZeneca, Kyowa Hakko Kirin, Chugai Pharma, Taiho Pharmaceutical, PfizerConsulting or Advisory Role: AstraZeneca, MSDResearch Funding: LillyNo other potential conflicts of interest were reported.

Comment in

  • Reply to Y. Kawamura et al.
    Loibl S, Nekljudova V, Denkert C. Loibl S, et al. J Clin Oncol. 2021 Sep 20;39(27):3090-3091. doi: 10.1200/JCO.21.01403. Epub 2021 Jul 6. J Clin Oncol. 2021. PMID: 34228503 No abstract available.

Comment on

  • Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer-The Penelope-B Trial.
    Loibl S, Marmé F, Martin M, Untch M, Bonnefoi H, Kim SB, Bear H, McCarthy N, Melé Olivé M, Gelmon K, García-Sáenz J, Kelly CM, Reimer T, Toi M, Rugo HS, Denkert C, Gnant M, Makris A, Koehler M, Huang-Bartelett C, Lechuga Frean MJ, Colleoni M, Werutsky G, Seiler S, Burchardi N, Nekljudova V, von Minckwitz G. Loibl S, et al. J Clin Oncol. 2021 May 10;39(14):1518-1530. doi: 10.1200/JCO.20.03639. Epub 2021 Apr 1. J Clin Oncol. 2021. PMID: 33793299 Clinical Trial.